Neurological recovery after XXXX : clinical feasibility trial of @entity460 blockers.

@entity1 @entity2399 @entity1855 @entity16 @entity460 @entity1167 @entity158
In order to determine whether the @entity460 blockers @entity1855 and/or @entity2399 decrease @entity16 after @entity1167 , all out-of-hospital @entity1167 (290) occurring during a nine-month period in five participating hospitals were retrospectively studied. Twenty-nine @entity1 met the criteria for inclusion in this study. Each had an unwitnessed, out-of-hospital @entity1167 and was comatose (no purposeful response to @entity158 ) 20 minutes after the restoration of spontaneous circulation (ROSC). Eighteen @entity1 ( @entity460 blocker group) received @entity1855 and/or @entity2399 at some point after ROSC, while eleven @entity1 received standard ACLS therapy (control group). Age, arrest time, cardiopulmonary resuscitation (CPR) time, and cerebral ischemic time were comparable in the two groups. In the @entity460 blocker group, seven of 18 @entity1 regained consciousness, and six of these seven survived. All six survivors appeared neurologically normal upon discharge and at three and six months of follow-up. While no demonstrably adverse effects were seen after the administration of @entity2399 , 56% of the @entity1 who received @entity1855 had a significant drop in blood pressure. In the control group, three of 11 @entity1 regained consciousness and two of the three left the hospital alive. Both survivors were disabled--one severely and one moderately. Follow-up after three and six months revealed no significant improvement in their disability. Overall, six of 18 @entity1 experienced clinically complete neurological recovery in the @entity460 blocker group, while none of the 11 @entity1 in the control group made a complete neurological recovery (P = 0.06).
